Quarterly Revenue Above Guidance Midpoint
Q1 2026 revenue of $147.5 million, +3.6% year-over-year, above the midpoint of guidance.
Strong Adjusted EBITDA and Margin
Q1 adjusted EBITDA of $40.7 million, representing a 27.6% adjusted EBITDA margin, exceeding the midpoint of guidance.
Pro Forma LTM Revenue and Margin
Pro forma trailing twelve months revenue roughly $596 million (adjusted for the ZyraTalk acquisition), +5.2% year-over-year, with an LTM adjusted EBITDA margin of ~29.7%.
Payments Scale and Growth in Top Solutions
Annualized total payments volume (TPV) of $12.9 billion. TPV in the top six solutions grew 19.8% year-over-year and now represents 35% of total TPV (up from 30% in 2025). Top-solution payments revenue grew 10% year-over-year and now represents over 46.5% of total payments revenue.
Multi-Solution Adoption Accelerating
301,000 customers enabled for more than one solution (+23% year-over-year) and ~131,000 customers actively utilizing more than one solution (+32% year-over-year). Multi-solution customers continue to generate net revenue retention (NRR) above 100% (company NRR = 95%).
Tangible AI-Driven Customer Outcomes
Service Fusion + ZyraTalk reduced technician mobilization from 24–48 hours to 4–6 hours (~60% efficiency gain in job management) and ZyraTalk booked over 30 jobs via AI interactions. EverHealth AI Scribe reduced clinical note time to ~10 minutes, saving ~1+ hour per day for a physician.
Liquidity, Deleveraging and Hedging
Ended Q1 with $129 million cash, $155 million undrawn revolver capacity (stepping down to $125 million in July 2026), $525 million debt outstanding and total net leverage of ~2.2x. $425 million of swaps hedged at a weighted average rate of 3.91%.
Cash Flow and Capital Returns
Q1 cash flow from continuing operations of $24.6 million (Q/Q $21.3M), levered free cash flow of $16.6 million (LTM levered FCF > $71M), adjusted unlevered free cash flow $25.3 million in the quarter and $121.6 million LTM. Repurchased ~1.3 million shares for $13.9 million in the quarter with ~$33.9 million remaining under a $300 million authorization.
Affirmed Full-Year and Q2 Guidance
Q2 2026 revenue guidance of $150.5M–$153.5M and adjusted EBITDA $41M–$43M. Full-year 2026 reiterated revenue guidance of $612M–$632M and adjusted EBITDA $183M–$191M.